Trial reportNature medicine2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).Nature cancer · 2025Trial
- Trial
- Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.Journal for immunotherapy of cancer · 2023Trial
- Combined PD-1, BRAF and MEK inhibition in BRAFNature medicine · 2023Trial
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With AdvancedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Anti-PD-1 Combinations: Triplets and Beyond.Current oncology reports · 2026Review
- Targeting CRTC2 reversesProceedings of the National Academy of Sciences of the United States of America · 2026Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer.Cancer cell international · 2026Review
- Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases.Frontiers in medicine · 2026Article
- Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.Signal transduction and targeted therapy · 2026Review
- The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis.Discover oncology · 2025Review
- Fragment-based discovery enables direct targeting of the melanoma oncogene MITF.Nature communications · 2025Article
- Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).Journal of hematology & oncology · 2025Review
- Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.Journal of translational medicine · 2025Article
- Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib.Journal of clinical medicine · 2025Review
- Gliomagenesis following chronic subdural hematoma: A case report.Experimental and therapeutic medicine · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 18 institutions in 11 countries.
Reinhard DummerUniversity Hospital Zürich Skin Cancer Center, Zurich, Switzerland. Reinhard.Dummer@usz.ch.ORCID http://orcid.org/0000-0002-2279-6906
Celeste LebbéAPHP Hôpital Saint-Louis, Dermatology and CIC, Université de Paris, Paris, France.
Victoria AtkinsonGreenslopes Private Hospital, Gallipoli Medical Research Foundation, University of Queensland, Greenslopes, Queensland, Australia.
Mario MandalàPapa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
Paul D NathanMount Vernon Cancer Centre, Northwood, UK.
Ana AranceHospital Clinic of Barcelona, Barcelona, Spain.
Erika RichtigMedical University of Graz, Graz, Austria.
Naoya YamazakiNational Cancer Center Hospital, Tokyo, Japan.
Caroline RobertGustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France.ORCID http://orcid.org/0000-0002-9493-0238
Dirk SchadendorfUniversity Hospital Essen, Essen and German Cancer Consortium, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-3524-7858
Hussein A TawbiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1942-851X
Paolo A AsciertoIstituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.ORCID http://orcid.org/0000-0002-8322-475X
Antoni RibasUniversity of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3669-8458
Keith T FlahertyMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3402-0478
Neha PakhleNovartis Healthcare Private Limited, Hyderabad, India.
Catarina D CampbellNovartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
Daniel GusenleitnerNovartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
Aisha MasoodNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Jan C BraseNovartis Pharma AG, Basel, Switzerland.
Eduard GasalNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8894-3545
Novartis (United States) · USHarvard University · USHeidelberg University · DEHospital Clínic de Barcelona · ESIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMedical University of Graz · ATMount Vernon Cancer Centre · GBNovartis (India) · INNovartis (Switzerland) · CHOspedale Papa Giovanni XXIII · ITThe University of Queensland · AUThe University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USTokyo National Hospital · JPUniversité Paris Cité · FRUniversité Paris-Saclay · FRUniversity Hospital of Zurich · CHUniversity of California, Los Angeles · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes
Indexed as
AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCohort StudiesDisease ProgressionFemaleHumansImidazolesImmune Checkpoint InhibitorsMaleMAP Kinase Kinase KinasesMelanomaMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, TumorBRAF protein, humandabrafenibImidazolesImmune Checkpoint InhibitorsMAP Kinase Kinase KinasesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesspartalizumabtrametinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.